$PYXS News

Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology Q1 EPS $(0.37), Inline

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Pyxis Oncology Appoints Thomas Civik As Interim CEO, Effective Immediately; Lara Sullivan Steps Down As President, CEO And Chief Medical Officer

Pyxis Oncology Appoints Thomas Civik As Interim CEO, Effective Immediately; Lara Sullivan Steps Down As President, CEO And Chief Medical Officer

3 Promising Penny Stocks With Market Caps Up To $300M

RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript